Literature DB >> 7675990

Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry.

D A Revicki1, B R Luce.   

Abstract

There is concern in developed countries about the increasing cost of health care. Developers of new psychopharmacologic agents are asked to demonstrate cost-effectiveness as well as safety and efficacy before widespread use is encouraged. Pharmacoeconomic studies are designed to evaluate the health outcomes and cost-effectiveness of new medical treatments relative to existing treatments. Retrospective and prospective research designs have been used in pharmacoeconomic studies. New approaches such as medical effectiveness studies and modeling studies based on clinical decision analysis are increasingly used to evaluate cost-effectiveness. This article introduces important concepts of pharmacoeconomic evaluation and discusses the methods and their strengths and weaknesses. Safety and efficacy studies and pharmacoeconomic studies provide useful and complementary evidence on how a new treatment affects clinical, health-related quality-of-life, and economic outcomes.

Mesh:

Substances:

Year:  1995        PMID: 7675990

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  15 in total

Review 1.  Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.

Authors:  D A Revicki; L Frank
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  A survey of population-based drug databases in Canada.

Authors:  E Miller; B Blatman; T R Einarson
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

3.  Quality of life rediscovered: implications for clinical outcome and health economics in schizophrenia.

Authors:  A G Awad
Journal:  J Psychiatry Neurosci       Date:  1997-07       Impact factor: 6.186

4.  Modelling the cost effectiveness of antidepressant treatment in primary care.

Authors:  D A Revicki; R E Brown; W Palmer; D Bakish; W W Rosser; S F Anton; D Feeny
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 5.  The economics of selective serotonin reuptake inhibitors in depression: a critical review.

Authors:  L Frank; D A Revicki; S V Sorensen; Y C Shih
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

Review 6.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 7.  Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Authors:  William A Hargreaves; P Joseph Gibson; Joseph P Gibson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 9.  Measuring quality of life in patients with schizophrenia.

Authors:  A G Awad; L N Voruganti; R J Heslegrave
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

10.  An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.

Authors:  Madeline Betancourt; Peggy S McKinnon; R Michael Massanari; Salmaan Kanji; David Bach; John W Devlin
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.